Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 28 entries
Sorted by: Best Match Show Resources per page
Broken detailed balance and entropy production in the human brain.

Proceedings of the National Academy of Sciences of the United States of America

Lynn CW, Cornblath EJ, Papadopoulos L, Bertolero MA, Bassett DS.
PMID: 34789565
Proc Natl Acad Sci U S A. 2021 Nov 23;118(47). doi: 10.1073/pnas.2109889118.

Living systems break detailed balance at small scales, consuming energy and producing entropy in the environment to perform molecular and cellular functions. However, it remains unclear how broken detailed balance manifests at macroscopic scales and how such dynamics support...

Cite
Lynn CW, Cornblath EJ, Papadopoulos L, et al. Broken detailed balance and entropy production in the human brain. Proc Natl Acad Sci U S A. 2021;118(47)doi: 10.1073/pnas.2109889118.
Lynn, C. W., Cornblath, E. J., Papadopoulos, L., Bertolero, M. A., & Bassett, D. S. (2021). Broken detailed balance and entropy production in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 118(47), . https://doi.org/10.1073/pnas.2109889118
Lynn, Christopher W, et al. "Broken detailed balance and entropy production in the human brain." Proceedings of the National Academy of Sciences of the United States of America vol. 118,47 (2021). doi: https://doi.org/10.1073/pnas.2109889118
Lynn CW, Cornblath EJ, Papadopoulos L, Bertolero MA, Bassett DS. Broken detailed balance and entropy production in the human brain. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47). doi: 10.1073/pnas.2109889118. PMID: 34789565; PMCID: PMC8617485.
Copy Download .nbib Format: NLM
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.

CPT: pharmacometrics & systems pharmacology

Tortorici MA, Yuraszeck T, Cornblath D, Bril V, Hartung HP, Sobue G, Lewis RA, Merkies ISJ, Lawo JP, Praus M, Durn BL, Mielke O, Ma X, Jauslin P, Pfister M, van Schaik IN.
PMID: 34085779
CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):839-850. doi: 10.1002/psp4.12647. Epub 2021 Aug 01.

The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received either subcutaneous Ig (IgPro20; Hizentra

Cite
Tortorici MA, Yuraszeck T, Cornblath D, et al. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):839-850doi: 10.1002/psp4.12647.
Tortorici, M. A., Yuraszeck, T., Cornblath, D., Bril, V., Hartung, H. P., Sobue, G., Lewis, R. A., Merkies, I. S. J., Lawo, J. P., Praus, M., Durn, B. L., Mielke, O., Ma, X., Jauslin, P., Pfister, M., van Schaik, I. N. (2021). Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT: pharmacometrics & systems pharmacology, 10(8), 839-850. https://doi.org/10.1002/psp4.12647
Tortorici, Michael A, et al. "Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy." CPT: pharmacometrics & systems pharmacology vol. 10,8 (2021): 839-850. doi: https://doi.org/10.1002/psp4.12647
Tortorici MA, Yuraszeck T, Cornblath D, Bril V, Hartung HP, Sobue G, Lewis RA, Merkies ISJ, Lawo JP, Praus M, Durn BL, Mielke O, Ma X, Jauslin P, Pfister M, van Schaik IN. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):839-850. doi: 10.1002/psp4.12647. Epub 2021 Aug 01. PMID: 34085779; PMCID: PMC8376132.
Copy Download .nbib Format: NLM
COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations.

Brain : a journal of neurology

Lunn MP, Cornblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, Willison HJ.
PMID: 33313690
Brain. 2021 Mar 03;144(2):357-360. doi: 10.1093/brain/awaa444.

No abstract available.

Cite
Lunn MP, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain. 2021;144(2):357-360doi: 10.1093/brain/awaa444.
Lunn, M. P., Cornblath, D. R., Jacobs, B. C., Querol, L., van Doorn, P. A., Hughes, R. A., & Willison, H. J. (2021). COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain : a journal of neurology, 144(2), 357-360. https://doi.org/10.1093/brain/awaa444
Lunn, Michael P, et al. "COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations." Brain : a journal of neurology vol. 144,2 (2021): 357-360. doi: https://doi.org/10.1093/brain/awaa444
Lunn MP, Cornblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, Willison HJ. COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain. 2021 Mar 03;144(2):357-360. doi: 10.1093/brain/awaa444. PMID: 33313690; PMCID: PMC7799242.
Copy Download .nbib Format: NLM
Neuro-ophthalmology: Five new things.

Neurology. Clinical practice

Cornblath WT.
PMID: 23634362
Neurol Clin Pract. 2012 Jun;2(2):129-133. doi: 10.1212/CPJ.0b013e31825a77de.

The field of neuro-ophthalmology is broad and interacts with other disciplines in neurology and ophthalmology along with neurosurgery, neuroradiology, rheumatology, and infectious disease. A number of interesting advances in diagnostic criteria, monitoring ability, and disease etiology have occurred in...

Cite
Cornblath WT. Neuro-ophthalmology: Five new things. Neurol Clin Pract. 2012;2(2):129-133doi: 10.1212/CPJ.0b013e31825a77de.
Cornblath, W. T. (2012). Neuro-ophthalmology: Five new things. Neurology. Clinical practice, 2(2), 129-133. https://doi.org/10.1212/CPJ.0b013e31825a77de
Cornblath, Wayne T. "Neuro-ophthalmology: Five new things." Neurology. Clinical practice vol. 2,2 (2012): 129-133. doi: https://doi.org/10.1212/CPJ.0b013e31825a77de
Cornblath WT. Neuro-ophthalmology: Five new things. Neurol Clin Pract. 2012 Jun;2(2):129-133. doi: 10.1212/CPJ.0b013e31825a77de. PMID: 23634362; PMCID: PMC3613196.
Copy Download .nbib Format: NLM
Oculopalatal tremor in multiple sclerosis with spontaneous resolution.

Neurology. Clinical practice

Sudhakar P, Parmar H, Cornblath WT.
PMID: 23634370
Neurol Clin Pract. 2012 Sep;2(3):255-257. doi: 10.1212/CPJ.0b013e31826af275.

No abstract available.

Cite
Sudhakar P, Parmar H, Cornblath WT. Oculopalatal tremor in multiple sclerosis with spontaneous resolution. Neurol Clin Pract. 2012;2(3):255-257doi: 10.1212/CPJ.0b013e31826af275.
Sudhakar, P., Parmar, H., & Cornblath, W. T. (2012). Oculopalatal tremor in multiple sclerosis with spontaneous resolution. Neurology. Clinical practice, 2(3), 255-257. https://doi.org/10.1212/CPJ.0b013e31826af275
Sudhakar, Padmaja, et al. "Oculopalatal tremor in multiple sclerosis with spontaneous resolution." Neurology. Clinical practice vol. 2,3 (2012): 255-257. doi: https://doi.org/10.1212/CPJ.0b013e31826af275
Sudhakar P, Parmar H, Cornblath WT. Oculopalatal tremor in multiple sclerosis with spontaneous resolution. Neurol Clin Pract. 2012 Sep;2(3):255-257. doi: 10.1212/CPJ.0b013e31826af275. PMID: 23634370; PMCID: PMC3613200.
Copy Download .nbib Format: NLM
Physiology of diabetes.

Pediatric annals

Maclaren NK, Cornblath M.
PMID: 24848984
Pediatr Ann. 1975 Jun 01;4(6):6-9. doi: 10.3928/0090-4481-19750601-06.

No abstract available.

Cite
Maclaren NK, Cornblath M. Physiology of diabetes. Pediatr Ann. 1975;4(6):6-9doi: 10.3928/0090-4481-19750601-06.
Maclaren, N. K., & Cornblath, M. (1975). Physiology of diabetes. Pediatric annals, 4(6), 6-9. https://doi.org/10.3928/0090-4481-19750601-06
Maclaren, N K, and Cornblath, M. "Physiology of diabetes." Pediatric annals vol. 4,6 (1975): 6-9. doi: https://doi.org/10.3928/0090-4481-19750601-06
Maclaren NK, Cornblath M. Physiology of diabetes. Pediatr Ann. 1975 Jun 01;4(6):6-9. doi: 10.3928/0090-4481-19750601-06. PMID: 24848984.
Copy Download .nbib Format: NLM
Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl.

Brain : a journal of neurology

Hughes RAC, Cornblath DR, Willison HJ.
PMID: 29106487
Brain. 2016 Nov 01;139(11):3041-3047. doi: 10.1093/brain/aww247.

No abstract available.

Cite
Hughes RAC, Cornblath DR, Willison HJ. Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain. 2016;139(11):3041-3047doi: 10.1093/brain/aww247.
Hughes, R. A. C., Cornblath, D. R., & Willison, H. J. (2016). Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain : a journal of neurology, 139(11), 3041-3047. https://doi.org/10.1093/brain/aww247
Hughes, Richard A C, et al. "Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl." Brain : a journal of neurology vol. 139,11 (2016): 3041-3047. doi: https://doi.org/10.1093/brain/aww247
Hughes RAC, Cornblath DR, Willison HJ. Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain. 2016 Nov 01;139(11):3041-3047. doi: 10.1093/brain/aww247. PMID: 29106487.
Copy Download .nbib Format: NLM
Thyroid Eye Disease.

Current treatment options in neurology

Cornblath WT.
PMID: 11096765
Curr Treat Options Neurol. 2000 Sep;2(5):401-406. doi: 10.1007/s11940-000-0038-6.

The treatment of thyroid eye disease is very complex, owing to the varied nature of the symptoms and the variable course of the disease. The first step in treatment should be achieving an euthyroid state or monitoring for the...

Cite
Cornblath WT. Thyroid Eye Disease. Curr Treat Options Neurol. 2000;2(5):401-406doi: 10.1007/s11940-000-0038-6.
Cornblath, W. T. (2000). Thyroid Eye Disease. Current treatment options in neurology, 2(5), 401-406. https://doi.org/10.1007/s11940-000-0038-6
Cornblath. "Thyroid Eye Disease." Current treatment options in neurology vol. 2,5 (2000): 401-406. doi: https://doi.org/10.1007/s11940-000-0038-6
Cornblath WT. Thyroid Eye Disease. Curr Treat Options Neurol. 2000 Sep;2(5):401-406. doi: 10.1007/s11940-000-0038-6. PMID: 11096765.
Copy Download .nbib Format: NLM
Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration.

The Journal of biological chemistry

Powell C, Cornblath E, Goldman D.
PMID: 25750264
J Biol Chem. 2015 Mar 06;290(10):6007. doi: 10.1074/jbc.A114.603043.

No abstract available.

Cite
Powell C, Cornblath E, Goldman D. Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration. J Biol Chem. 2015;290(10):6007doi: 10.1074/jbc.A114.603043.
Powell, C., Cornblath, E., & Goldman, D. (2015). Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration. The Journal of biological chemistry, 290(10), 6007. https://doi.org/10.1074/jbc.A114.603043
Powell, Curtis, et al. "Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration." The Journal of biological chemistry vol. 290,10 (2015): 6007. doi: https://doi.org/10.1074/jbc.A114.603043
Powell C, Cornblath E, Goldman D. Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration. J Biol Chem. 2015 Mar 06;290(10):6007. doi: 10.1074/jbc.A114.603043. PMID: 25750264; PMCID: PMC4358241.
Copy Download .nbib Format: NLM
Introduction.

Pediatric annals

Maclaren NK, Cornblath M.
PMID: 24847837
Pediatr Ann. 1975 Jun 01;4(6):5. doi: 10.3928/0090-4481-19750601-05.

No abstract available.

Cite
Maclaren NK, Cornblath M. Introduction. Pediatr Ann. 1975;4(6):5doi: 10.3928/0090-4481-19750601-05.
Maclaren, N. K., & Cornblath, M. (1975). Introduction. Pediatric annals, 4(6), 5. https://doi.org/10.3928/0090-4481-19750601-05
Maclaren, N K, and Cornblath, M. "Introduction." Pediatric annals vol. 4,6 (1975): 5. doi: https://doi.org/10.3928/0090-4481-19750601-05
Maclaren NK, Cornblath M. Introduction. Pediatr Ann. 1975 Jun 01;4(6):5. doi: 10.3928/0090-4481-19750601-05. PMID: 24847837.
Copy Download .nbib Format: NLM
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.

Brain : a journal of neurology

Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E.
PMID: 35038723
Brain. 2022 Jan 17; doi: 10.1093/brain/awab422. Epub 2022 Jan 17.

Intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy usually starts with a 2.0 g/kg induction dose followed by 1.0 g/kg maintenance doses every 3 weeks. No dose-ranging studies with intravenous immunoglobulin maintenance therapy have been published. The Progress in...

Cite
Cornblath DR, van Doorn PA, Hartung HP, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;doi: 10.1093/brain/awab422.
Cornblath, D. R., van Doorn, P. A., Hartung, H. P., Merkies, I. S. J., Katzberg, H. D., Hinterberger, D., Clodi, E. (2022). Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain : a journal of neurology, . https://doi.org/10.1093/brain/awab422
Cornblath, David R, et al. "Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy." Brain : a journal of neurology vol. (2022). doi: https://doi.org/10.1093/brain/awab422
Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022 Jan 17; doi: 10.1093/brain/awab422. Epub 2022 Jan 17. PMID: 35038723.
Copy Download .nbib Format: NLM
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

Journal of the peripheral nervous system : JPNS

Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA.
PMID: 34085743
J Peripher Nerv Syst. 2021 Sep;26(3):242-268. doi: 10.1111/jns.12455. Epub 2021 Jul 30.

To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted...

Cite
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242-268doi: 10.1111/jns.12455.
Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S., Blomkwist-Markens, P. H., Cornblath, D. R., Eftimov, F., Goedee, H. S., Harbo, T., Kuwabara, S., Lewis, R. A., Lunn, M. P., Nobile-Orazio, E., Querol, L., Rajabally, Y. A., Sommer, C., & Topaloglu, H. A. (2021). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. Journal of the peripheral nervous system : JPNS, 26(3), 242-268. https://doi.org/10.1111/jns.12455
Van den Bergh, Peter Y K, et al. "European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision." Journal of the peripheral nervous system : JPNS vol. 26,3 (2021): 242-268. doi: https://doi.org/10.1111/jns.12455
Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep;26(3):242-268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. PMID: 34085743.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 28 entries